GR3036505T3 - Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman - Google Patents

Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman

Info

Publication number
GR3036505T3
GR3036505T3 GR20010401365T GR20010401365T GR3036505T3 GR 3036505 T3 GR3036505 T3 GR 3036505T3 GR 20010401365 T GR20010401365 T GR 20010401365T GR 20010401365 T GR20010401365 T GR 20010401365T GR 3036505 T3 GR3036505 T3 GR 3036505T3
Authority
GR
Greece
Prior art keywords
dihydrobenzisothiazol
dioxido
chroman
aminomethyl
oxo
Prior art date
Application number
GR20010401365T
Other languages
English (en)
Inventor
Alfons Dr Grunenberg
Oliver Dr Brehm
Michael Dr Conrad
Dietrich Dr Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of GR3036505T3 publication Critical patent/GR3036505T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
GR20010401365T 1995-11-22 2001-08-31 Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman GR3036505T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (1)

Publication Number Publication Date
GR3036505T3 true GR3036505T3 (en) 2001-11-30

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010401365T GR3036505T3 (en) 1995-11-22 2001-08-31 Crystalline hydrochloride of (R)-(-)-2-[N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]-aminomethyl]-chroman

Country Status (32)

Country Link
US (1) US5830908A (el)
EP (1) EP0775704B1 (el)
JP (1) JPH09143180A (el)
KR (1) KR970027079A (el)
CN (1) CN1086703C (el)
AR (1) AR004961A1 (el)
AT (1) ATE201872T1 (el)
AU (1) AU712922B2 (el)
BR (1) BR9605646A (el)
CA (1) CA2190700A1 (el)
CZ (1) CZ289730B6 (el)
DE (2) DE19543478A1 (el)
DK (1) DK0775704T3 (el)
EE (1) EE9600183A (el)
ES (1) ES2159342T3 (el)
GR (1) GR3036505T3 (el)
HU (1) HUP9603237A3 (el)
IL (1) IL119647A (el)
MX (1) MX9605741A (el)
MY (1) MY132473A (el)
NO (1) NO307340B1 (el)
NZ (1) NZ299780A (el)
PL (1) PL317090A1 (el)
PT (1) PT775704E (el)
RU (1) RU2181723C2 (el)
SG (1) SG44989A1 (el)
SI (1) SI0775704T1 (el)
SK (1) SK150096A3 (el)
TR (1) TR199600930A2 (el)
TW (1) TW449595B (el)
UA (1) UA45338C2 (el)
ZA (1) ZA969753B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748182A (en) * 1986-03-05 1988-05-31 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives and their use as anti-hypertensive and anxiolytic agents
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
EE9600183A (et) 1997-06-16
MX9605741A (es) 1997-05-31
PT775704E (pt) 2001-09-28
ES2159342T3 (es) 2001-10-01
ZA969753B (en) 1997-03-25
TR199600930A2 (tr) 1997-06-21
NO307340B1 (no) 2000-03-20
HU9603237D0 (en) 1997-01-28
HUP9603237A3 (en) 1998-12-28
MY132473A (en) 2007-10-31
BR9605646A (pt) 1998-08-18
NZ299780A (en) 1998-09-24
UA45338C2 (uk) 2002-04-15
IL119647A0 (en) 1997-02-18
IL119647A (en) 1999-12-22
CN1086703C (zh) 2002-06-26
AU7177296A (en) 1997-05-29
PL317090A1 (en) 1997-05-26
CZ289730B6 (cs) 2002-03-13
AR004961A1 (es) 1999-04-07
ATE201872T1 (de) 2001-06-15
SK150096A3 (en) 1997-08-06
CA2190700A1 (en) 1997-05-23
TW449595B (en) 2001-08-11
US5830908A (en) 1998-11-03
DE19543478A1 (de) 1997-05-28
KR970027079A (ko) 1997-06-24
JPH09143180A (ja) 1997-06-03
CN1152574A (zh) 1997-06-25
EP0775704B1 (de) 2001-06-06
NO964950L (no) 1997-05-23
RU2181723C2 (ru) 2002-04-27
CZ342896A3 (en) 1997-06-11
AU712922B2 (en) 1999-11-18
NO964950D0 (no) 1996-11-21
SI0775704T1 (en) 2001-08-31
DE59607040D1 (de) 2001-07-12
EP0775704A1 (de) 1997-05-28
DK0775704T3 (da) 2001-07-23
SG44989A1 (en) 1997-12-19
HUP9603237A2 (hu) 1998-01-28

Similar Documents

Publication Publication Date Title
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
PL300235A1 (en) 5-{2-[4-(1,2-benzoisothiazolyl-3)-1-piperozinyl] ethyl}-6-chloro-1,3-dihydro-2h-indolone-2 hydrochloride monohydrate
SG43787A1 (en) Novel paroxetine hydrochloride anhydrate
CA2304568A1 (en) Olanzapine pamoate formulations
NZ328387A (en) 4-[2-(n-(heteroaryl)-hydrazonoethyloxy)]benzoyl-2-benzyloxy-carbonylamino-alanine derivatives and medicaments containing them
PL334184A1 (en) Fungicidal compositions based on methyl n-(phenylacetyl)-n-(2,6-xylyl) alaninate
NO965084D0 (no) N-[3(3-cyanopyrazol[1,5-aÅpyrimidin-7-yl)fenylÅ-N-etyl-acetamid
NZ299788A (en) 4-substituted(4-(1-adamantyl)phenyl) derivatives
PL346981A1 (en) 2-methyl-thieno-benzodiazepine formulation
NO975220L (no) Ny fremgangsmåte for fremstilling av ropivacainhydrokloridmonohydrat
PL344994A1 (en) Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems
IL136590A0 (en) Process for preparation of paroxetine hydrochloride
NO974846D0 (no) Fremgangsmåte for fremstilling av Form 1 Ranitidin-Hydroklorid
AU1479800A (en) Procedure for synthesis of N-(2(((5-((dialkilamino) methyl)-2- furanyl) methyl)thyo) ethyl)-N'- alkyl-2-nitro1,1 alkenediamines and their hydrochlorides
PL353243A1 (en) An improved form of form i celiprolol hydrochloride
AU7492496A (en) Salts of N-(4-oxo-2-(1H-tetrazoyl-5-yl)-4H-1-benzopyran-8-yl)-4-(4-ph enylbutoxy)benzamide
ZA985156B (en) Elevation of HDL cholesterol by N-[4-[(aminothioxomethyl)hydrazono]-4-arylbutyl]amides.
HUP9701695A3 (en) Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis
LT96007A (en) Paroxetine hydrochloride anhydrate and process for preparing thereof
HK1008990A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
SI1242389T1 (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h(1,2,4)triazol, methods for producing them and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees